Nexalin Technology, Inc. (NXL) announced Thursday the launch of NeuroCare, its new AI-designed virtual clinic platform created in collaboration with the University of California, San Diego. If you've ever thought "wouldn't it be nice to get medical treatment without leaving my house," this is precisely that idea applied to brain health.
The launch represents the first deployment of Nexalin's digital health ecosystem, which aims to expand patient access, lower treatment costs, and deliver ongoing physician oversight across a range of brain-health conditions. It's essentially taking what used to require clinical visits and making it work from your couch.
This collaboration builds on Nexalin's existing clinical research partnership with UC San Diego, where patient enrollment has already begun in trials evaluating the company's non-invasive Deep Intracranial Frequency Stimulation technology. The research relationship is now expanding into real-world application.
How the Technology Works
The NeuroCare digital platform connects with Nexalin's next-generation Gen-3 HALO headset, which delivers enhanced Deep Intracranial Frequency Stimulation (DIFS) in home environments. The clinical trial at UC San Diego marks the official debut of this Gen-3 HALO headset, which is now managed and monitored remotely through the NeuroCare virtual clinic during treatment sessions.
Through the platform, patients dealing with Alzheimer's and dementia, mood disorders like depression and anxiety, and military-related conditions including traumatic brain injury and post-traumatic stress disorder can access Nexalin's frequency-based neurostimulation treatment without leaving home. The HALO headset administers the therapy while physicians monitor progress remotely.
The NeuroCare platform provides remote treatment monitoring, enhanced privacy, and continuity of care within a subscription-based business model designed to support sustainable revenue and long-term patient outcomes. Patients can start care through secure remote channels without physically visiting a clinic, eliminating waiting rooms, reducing physician overhead, and bypassing the stigma some patients experience by offering treatment in private, home-based settings. Real-time monitoring tools keep physicians connected to patient progress.
The Research Behind It
Earlier this week, Nexalin highlighted peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. The company is building a growing body of evidence supporting the approach.
Last October, the company announced publication of positive clinical data in Radiology demonstrating that its proprietary 15 milliamp Gen-2 Nexalin DIFS technology—an advanced implementation of transcranial alternating current stimulation—improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease. That's the kind of hard data that moves technology from "interesting concept" to "legitimate treatment option."
Price Action: NXL stock traded up 11.51% at $0.63 during Thursday's premarket session.
